ICICI Pru Pharma Healthcare Diag Gr

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is an open-ended sectoral (healthcare) equity mutual fund that focuses on the healthcare ecosystem.

It invests primarily in equity and equity-related instruments of companies involved in pharmaceuticals, medical services and diagnostic solutions.

A small portion may be allocated to cash or money market instruments for liquidity management, which is standard across mutual funds.

The scheme may be suitable for investors looking for sector-focused exposure within healthcare and who can accept a very high-risk profile.

Pros

The scheme follows a sector-specific approach centered on healthcare-related industries. It is structured for investors who want participation in companies involved in medical services, treatment solutions, and healthcare delivery systems. The defined theme provides clarity in portfolio composition, though it also introduces concentration risk.

1. Coverage across the healthcare value chain

The portfolio consists of companies operating in domains like pharmaceuticals, hospital services and diagnostics. There is exposure across multiple stages of healthcare delivery, from manufacturing to patient services, although allocation may be skewed toward pharmaceutical companies.

2. Inclusion of service and product-oriented businesses

The scheme invests in both product-based companies and service providers. These include drug manufacturers, hospitals and diagnostic centres.  This broadens exposure within the healthcare theme, though weight allocation across segments may vary.

3. Clearly defined thematic allocation

The scheme typically allocates within healthcare-related sectors. Hence, investors gain a clear understanding of how investments are distributed across various segments within the theme, subject to portfolio concentration in select sub-sectors.

4. Equity-driven portfolio structure

The scheme has a high allocation to equity instruments, and thus, it reflects its focus on healthcare-linked companies. This results in returns being closely linked to equity market movements and healthcare sector cycles.

Cons

The scheme maintains a focused allocation within pharmaceutical, healthcare, and diagnostics equities. It carries a very high risk profile and may not be suitable for investors seeking diversification or stability over shorter investment horizons. The portfolio’s structure makes it highly sensitive to sector-specific developments.

1. Concentration within healthcare-related sectors

This type of investment is restricted to the pharma, healthcare and diagnostics sector.

This aspect limits diversification and increases the impact of sector-specific risks on portfolio performance.

It may also be less flexible in allocating capital outside the defined healthcare universe.

2. Reliance on regulatory and approval processes

The businesses functioning in this segment usually comply with a highly regulated environment (including domestic and international regulators such as the USFDA).

Therefore, changes in approvals, compliance requirements or regulatory conditions can significantly impact operations, product launches, and revenue visibility.

Changes to regulatory timelines or requirements may also affect operational planning and execution.

3. Exposure to industry-specific operating conditions

The portfolio reflects changes in related healthcare industries.

Factors such as pricing pressure (especially in export markets), currency movements, and R&D pipeline outcomes can impact company performance.

As a result, the portfolio value may fluctuate over time, especially during periods of regulatory shifts, demand changes, or global healthcare market volatility.

4. High portfolio concentration risk 

The fund exhibits high concentration risk, with a significant portion of assets allocated to a limited number of stocks (top 10 holdings 60%+) and healthcare sub-sectors (97%+).

This increases sensitivity to individual stock performance and sector-specific downturns.